Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 4889 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response (in 

hours) 

Total burden 

(in hours) 

Consumers .................... Be Antibiotics Aware Consumer Pilot Assessment Pretest.50 1 20/60 17 

Consumers .................... Be Antibiotics Aware Consumer Pilot Assessment Posttest.50 1 20/60 17 

HCPs ............................. HCP Be Antibiotics Aware Campaign Pretest .... 50 1 20/60 17 

HCPs ............................. Be Antibiotics Aware Posttest ............................. 50 1 20/60 17 

Total ........................ .............................................................................. ........................ ........................ ........................ 68 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Scientific Integrity, Office of Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2022–01886 Filed 1–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2022–0015] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. Time will be available for public 

comment. The meeting will be webcast 

live via the World Wide Web. 

DATES: The meeting will be held on 

February 23–24, 2022, from 10:00 a.m. 

to 5:00 p.m., EST (times subject to 

change). Written comments must be 

received on or before February 24, 2022. 

ADDRESSES: You may submit comments 

identified by Docket No. CDC–2022– 

0015 by either of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027, Attn: ACIP Meeting. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

Written public comments submitted 

72 hours prior to the ACIP meeting will 

be provided to ACIP members before the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, National Center 

for Immunization and Respiratory 

Diseases, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, Georgia 30329– 

4027; Telephone: (404) 639–8367; 

Email: ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The committee is charged 

with advising the Director, CDC, on the 

use of immunizing agents. In addition, 

under 42 U.S.C. 1396s, the committee is 

mandated to establish and periodically 

review and, as appropriate, revise the 

list of vaccines for administration to 

vaccine-eligible children through the 

Vaccines for Children (VFC) program, 

along with schedules regarding dosing 

interval, dosage, and contraindications 

to administration of vaccines. Further, 

under provisions of the Affordable Care 

Act, section 2713 of the Public Health 

Service Act, immunization 

recommendations of the ACIP that have 

been approved by the CDC Director and 

appear on CDC immunization schedules 

must be covered by applicable health 

plans. 

Matters To Be Considered: The agenda 

will include discussions on, hepatitis B 

vaccines, influenza vaccines, 

pneumococcal vaccine, cholera vaccine, 

human papillomavirus vaccine, MMR 

vaccine, respiratory syncytial virus 

vaccine, and tickborne encephalitis 

vaccine. Recommendation votes on 

cholera vaccine and tickborne 

encephalitis vaccine are scheduled. No 

Vaccines for Children (VFC) votes are 

scheduled. Agenda items are subject to 

change as priorities dictate. For more 

information on the meeting agenda visit 

https://www.cdc.gov/vaccines/acip/ 

meetings/meetings-info.html. 

Public Participation 

Interested persons or organizations 

are invited to participate by submitting 

written views, recommendations, and 

data. Please note that comments 

received, including attachments and 

other supporting materials, are part of 

the public record and are subject to 

public disclosure. Comments will be 

posted on https://www.regulations.gov. 

Therefore, do not include any 

information in your comment or 

supporting materials that you consider 

confidential or inappropriate for public 

disclosure. If you include your name, 

contact information, or other 

information that identifies you in the 

body of your comments, that 

information will be on public display. 

CDC will review all submissions and 

may choose to redact, or withhold, 

submissions containing private or 

proprietary information such as Social 

Security numbers, medical information, 

inappropriate language, or duplicate/ 

near duplicate examples of a mass-mail 

campaign. CDC will carefully consider 

all comments submitted into the docket. 

Written Public Comment: Written 

comments must be received on or before 

February 24, 2022. 

Oral Public Comment: This meeting 

will include time for members of the 

public to make an oral comment. Oral 

public comment will occur before any 

scheduled votes including all votes 

relevant to the ACIP’s Affordable Care 

Act and Vaccines for Children Program 

roles. Priority will be given to 

individuals who submit a request to 

make an oral public comment before the 

meeting according to the procedures 

below. 

Procedure for Oral Public Comment: 

All persons interested in making an oral 

public comment at the February 23–24, 

2022, ACIP meeting must submit a 

request at http://www.cdc.gov/vaccines/ 


khammond on DSKJM1Z7X2PROD with NOTICES
4890 Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices 

acip/meetings/ no later than 11:59 p.m., 

EST, February 21, 2022, according to the 

instructions provided. 

If the number of persons requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

time, CDC will conduct a lottery to 

determine the speakers for the 

scheduled public comment session. 

CDC staff will notify individuals 

regarding their request to speak by email 

by February 22, 2022. To accommodate 

the significant interest in participation 

in the oral public comment session of 

ACIP meetings, each speaker will be 

limited to 3 minutes, and each speaker 

may only speak once per meeting. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–01820 Filed 1–28–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–22–22CB; Docket No. CDC–2022– 

0011] 

Proposed Data Collection Submitted 

for Public Comment and 

Recommendations 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), as part of 

its continuing effort to reduce public 

burden and maximize the utility of 

government information, invites the 

general public and other Federal 

Agencies the opportunity to comment 

on a proposed and/or continuing 

information collection, as required by 

the Paperwork Reduction Act of 1995. 

This notice invites comment on a 

proposed information collection project 

titled Assessment for the Get Ahead of 

Sepsis (GAOS) Consumer Campaign. 

This assessment collects on-line survey 

data from target consumer groups and 

healthcare professionals (HCP) before 

and after the campaign. 

DATES: CDC must receive written 

comments on or before April 1, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0011 by either of the following methods: 

• Federal eRulemaking Portal: 

Regulations.gov. Follow the instructions 

for submitting comments. 

• Mail: Jeffrey M. Zirger, Information 

Collection Review Office, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE, MS H21–8, Atlanta, 

Georgia 30329. 

Instructions: All submissions received 

must include the agency name and 

Docket Number. CDC will post, without 

change, all relevant comments to 

regulations.gov. 

Please note: Submit all comments 

through the Federal eRulemaking portal 

(regulations.gov) or by U.S. mail to the 

address listed above. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plan and 

instruments, contact Jeffrey M. Zirger, 

Information Collection Review Office, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, MS 

H21–8, Atlanta, Georgia 30329; phone: 

404–639–7570; Email: omb@cdc.gov. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), Federal Agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. In addition, the PRA also 

requires federal agencies to provide a 

60-day notice in the Federal Register 

concerning each proposed collection of 

information, including each new 

proposed collection, each proposed 

extension of existing collection of 

information, and each reinstatement of 

previously approved information 

collection before submitting the 

collection to the OMB for approval. To 

comply with this requirement, we are 

publishing this notice of a proposed 

data collection as described below. 

The OMB is particularly interested in 

comments that will help: 

1. Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

2. Evaluate the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

3. Enhance the quality, utility, and 

clarity of the information to be 

collected; 

4. Minimize the burden of the 

collection of information on those who 

are to respond, including through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submissions 

of responses; and 

5. Assess information collection costs. 

Proposed Project 

Assessment for the Get Ahead of 

Sepsis (GAOS) Consumer Campaign— 

New—National Center for Emerging and 

Zoonotic Infectious Diseases (NCEZID), 

Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

Sepsis is a life threating emergency, 

and it is the body’s overactive and toxic 

response to an infection. Each year 1.7 

million adults in the United States 

develop sepsis, with 270,000 fatalities. 

Sepsis is the leading cause of death in 

hospitals and one out of three hospital 

fatalities are due to sepsis infection. 

Sepsis management in U.S. hospitals is 

the highest when compared to inpatient 

cost for all other medical conditions. 

Annual costs are estimated to be over 

$62 billion. 

In media and public health 

campaigns, antimicrobial resistance and 

sepsis are rarely presented together 

which does not make their linkage 

apparent. It has been concluded that 

sepsis and antimicrobial stewardship 

should not be discussed in isolation. 

Surprisingly, 24 percent of adults in the 

U.S. have never heard of sepsis, so this 

presents a unique opportunity for future 

messaging campaigns. 

The goals of the GAOS educational 

campaign are to prevent and reduce 

infections that lead to sepsis and to 

optimize healthcare quality and patient 

safety by raising awareness, knowledge, 

and motivating behavior change related 

to sepsis prevention, early recognition, 

and appropriate treatment among 

consumer target audiences. A panel 

survey will be utilized to recruit 

participants. Surveys will be distributed 

to consumer target groups and HCPs 

both before and after the media 

campaign and partner outreach. 

Consumer audiences include: 

(1) Cancer patients and their 

caregivers (English speaking), 

(2) Patients who survived severe 

COVID–19 or sepsis and their caregivers 

(English speaking), 


khammond on DSKJM1Z7X2PROD with NOTICES